AKT3 and triple-negative breast carcinoma: For example, Banerji et al. identified a recurrent MAGI3-AKT3 fusion enriched in triple-negative breast cancer that leads to constitutive activation of AKT kinase, which can be targeted with an ATP-competitive AKT small-molecule inhibitor [39].